Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

Size: px

Start display at page:

Download "Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma"

Janel Flowers
5 years ago
Views:

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in

It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of

1 Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the adjuvant/curative/neo-adjuvant setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors. Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent. Regimen Code BEACOPP Etoposide 200 mg/m² IV days 1-3; DOXOrubicin 35 mg/m² IV day 1; Cyclophosphamide 1250 mg/m² IV day 1; Procarbazine 100 mg/m² PO daily, days 1-7; Prednisone 40 mg/m² PO daily, days 1-14; Bleomycin 10 mg/m² IV day 8; vincristine 1.4 mg/m 2 (max 2 mg) IV day 8. CEOP Cyclophosphamide 750 mg/m² IV day 1; Etoposide 50 mg/m² IV day 1; Etoposide 100 mg/m² PO days 2-3; Vincristine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO daily on days 1-5. CEOP+RITU Cyclophosphamide 750 mg/m² IV day 1; Etoposide 50 mg/m² IV day 1; Etoposide 100 mg/m² PO days 2-3; Vincristine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO daily on days 1-5; CEPP(B) Cyclophosphamide mg/m² IV days 1, 8; Etoposide 70 mg/m² IV days 1, 2, 3; Procarbazine 60 mg/m² PO daily, days 1-10; Prednisone 60mg/m² PO daily, days 1-10; Bleomycin 15 units/m² IV days 1, 15. Alternative Etoposide schedule: 70 mg/m² IV day 1 and 140 mg/m² PO daily, days 2 and 3

2 Procarbazine may be dropped from the regimen CEPIOP Cyclophosphamide 750 mg/m² IV day 1; epirubicin 50mg/m² IV day 1; Prednisone 100 mg PO daily, days 1-5. CEPIOP+RITU Cyclophosphamide750 mg/m² IV day 1; epirubicin 50 mg/m² IV day 1; CEPP Cyclophosphamide mg/m² IV days 1 and 8; Etoposide 70 mg/m² IV day 1; Etoposide 140 mg/m² PO days 2-3; Procarbazine 60 mg/m² PO daily, days 1-10; Prednisone 60 mg/m² PO daily, days CEPP+RITU Cyclophosphamide mg/m² IV days 1 and 8; Etoposide 70 mg/m² IV day 1; Etoposide 140 mg/m² PO day 2-3; Procarbazine 60 mg/m² PO daily, day 1-10; Prednisone 60 mg/m² PO daily, days 1-10; rituximab 375mg/m² IV day 1. CHOEP Cyclophosphamide 750 mg/m² IV day 1; Etoposide 100 mg/m² IV day 1; Etoposide 200 mg/m² PO days 2-3; Prednisone 100 mg PO daily, days 1-5. CHOEP+RITU Cyclophosphamide 750 mg/m² IV day 1; Etoposide 100 mg/m² IV day 1 ; Etoposide 200 mg/m² PO days 2-3;

3 Regimen Code CHOP Cyclophosphamide 750 mg/m² IV day 1; Prednisone 100 mg PO daily, days 1-5. CHOP+R Cyclophosphamide 750 mg/m² IV day 1; CHOP14+R Cyclophosphamide 750 mg/m² IV day 1; Q14 days CNOP Cyclophosphamide 750 mg/m² IV day 1; MitoXANTRONE 10 mg/m² IV day 1; Prednisone 50 mg/m²/day PO days 1-5. CYCLETOP Cyclophosphamide 2000 mg/m² IV day 1; Etoposide 200 mg/m² IV days 1-3. CYTAMTRX(IT) DHAP ESHAP EPOCH+RITU Schedule and frequency is variable, one option is: Methotrexate 12 mg + Cytarabine 40 mg IT +/- Hydrocortisone 15 mg IT 2 injections/week for 4 weeks CISplatin 100 mg/m² IV day 1; Cytarabine 2000 mg/m² IV over 2 hours Q12 hours x 2 doses, day 2; Dexamethasone 40 mg PO days 1-4. Etoposide 40 mg/m²/day IV days 1-4; CISplatin 25 mg/m²/day CIV days 1-4; Cytarabine 2000 mg/m² IV day 5 only; Methylprednisolone 500 mg IV days 1-5; rituximab 375 mg/m 2 IV day 1 (before starting EPOCH); Etoposide 50 mg/m 2 /day CIV days 1 to 4; vincristine 0.4 mg/m 2 /day CIV days 1 to 4; DOXOrubicin 10 mg/m 2 /day CIV days 1 to 4; Cyclophosphamide 750 mg/m 2 IV day 5; Prednisone 60 mg/m 2 PO daily or BID days 1 to 5

4 Note: this is dose-adjusted EPOCH GDP Gemcitabine 1000 mg/m² IV days 1,8; Dexamethasone 40 mg PO days 1-4; CISplatin 75 mg/m² IV day 1. HYPERCVAD Course A: Cyclophosphamide 600 mg/m² IV days 1-3 (max 1320 mg); DOXOrubicin 50 mg/m² IV day 4*; vincristine 1.4 mg/m² (max 2 mg) IV days 4* and 11; Dexamethasone 40 mg PO days 1, 2, 3, 4, 11, 12, 13, 14. *some centres may administer on day 3 HYPERCVAD+RITU Course B: Inpatient Course A: Cyclophosphamide 600 mg/m² IV days 1-3 (max 1320 mg); DOXOrubicin 50 mg/m² IV day 4*; vincristine 1.4 mg/m² (max 2 mg) IV days 4* and 11; Dexamethasone 40 mg PO days 1, 2, 3, 4, 11, 12, 13, 14; *some centres may administer on day 3 ICE Course B: Inpatient Mesna 1667 mg/m² IV days 1-3; Ifosfamide 1667 mg/m² IV days 1-3; Mesna 2000 mg PO days 1-3 (2 and 4 hours post-ifosfamide); CARBOplatin AUC 5 IV day 1; Etoposide 100 mg/m² IV days 1-3.

5 MINIBEAM MTRX(IT) Carmustine 60 mg/m² IV day 1; Etoposide 75 mg/m² IV days 2-5; Cytarabine 100 mg/m² IV Q12 hours, days 2-5; Melphalan 30 mg/m² IV day 6 (or may give 6 mg/m² IV daily for 5 days, or entire dose on day 5 for outpatient administration). Q28-42 days Methotrexate 12 mg IT Schedule and frequency depends on treatment intent and disease status (i.e. prophylactic or established CNS involvement) GDP+RITU Gemcitabine 1000 mg/m² IV days 1 and 8; Dexamethasone 40 mg PO days 1-4; CISplatin 75 mg/m² IV day 1; rituximab 375 mg/m² IV day 1 Not currently publicly funded for this regimen and intent RITU(IT) rituximab mg IT once or twice weekly for up to 8 injections not currently publicly funded for this regimen and intent

6 CODOXM Burkitt s Lymphoma : cyclophosphamide 800 mg/m² IV day 1; DOXOrubicin 40 mg/m² IV day 1; vincristine 1.5 mg/m² (max 2 mg) IV days 1, 8 (also day 15 in cycle 3); Cytarabine 70mg IT days 1, 3; cyclophosphamide 200 mg/m² IV days 2-5; Inpatient Methotrexate 1200 mg/m² IV day 10; Inpatient Methotrexate 240 mg/m² /hour x 23 hours, CIV day 10; Inpatient Leucovorin 192 mg/m² IV 12 hours post-methotrexate day 11; Inpatient Leucovorin 12 mg/m² IV Q6 hours until Methotrexate clear. CODOXM+RITU : Cyclophosphamide 800 mg/m² IV day 1; DOXOrubicin 40 mg/m² IV day 1; vincristine 1.5 mg/m² (max 2 mg) IV days 1 and 8 (also day 15 in cycle 3); Cytarabine 70 mg IT days 1 and 3; rituximab 375 mg/m² IV day 1*; Cyclophosphamide 200 mg/m² IV days 2-5; Inpatient Methotrexate 1200 mg/m² IV day 10; Inpatient Methotrexate 240 mg/m² /hour x 23 hours, CIV day 10; Inpatient Leucovorin 192 mg/m² IV 12 hours post-methotrexate day 11; Inpatient Leucovorin 12 mg/m² IV Q6 hours until Methotrexate clear. EPOCH+RITU *dose may be postponed to later in the cycle if clinically indicated rituximab 375 mg/m 2 IV day 1 (before starting EPOCH); Etoposide 50 mg/m 2 /day CIV days 1 to 4; vincristine 0.4 mg/m 2 /day CIV days 1 to 4; DOXOrubicin 10 mg/m 2 /day CIV days 1 to 4; Cyclophosphamide 750 mg/m 2 IV day 5; Prednisone 60 mg/m 2 PO daily or BID days 1 to 5 Note: this is dose-adjusted EPOCH Last Updated: February 2017

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for low grade lymphoma and Hairy Cell leukemia used in the palliative